6/3000008626686/3010-Q9/30/20262027Q1FALSEFALSE0-20127FALSEtrueTRUEfalse0.0010.00135,000,00035,000,0007,415,3297,415,3297,415,3297,415,3290.0010.0012,000,0002,000,0002,000,0002,000,000OTHER INFORMATIONOTHER INFORMATIONOTHER INFORMATIONOTHER INFORMATIONxbrli:sharesiso4217:USDxbrli:sharesiso4217:USDxbrli:pure00008626682026-07-012026-09-3000008626682026-11-1300008626682026-05-1400008626682026-09-3000008626682026-06-300000862668us-gaap:SecuredDebtMember2026-09-300000862668us-gaap:SecuredDebtMember2026-06-300000862668us-gaap:ProductMember2026-07-012026-09-300000862668us-gaap:ProductMember2025-07-012025-09-300000862668us-gaap:ServiceMember2026-07-012026-09-300000862668us-gaap:ServiceMember2025-07-012025-09-3000008626682025-07-012025-09-300000862668us-gaap:PreferredStockMember2026-06-300000862668us-gaap:CommonStockMember2026-06-300000862668us-gaap:AdditionalPaidInCapitalMember2026-06-300000862668us-gaap:RetainedEarningsMember2026-06-300000862668us-gaap:PreferredStockMember2026-07-012026-09-300000862668us-gaap:CommonStockMember2026-07-012026-09-300000862668us-gaap:AdditionalPaidInCapitalMember2026-07-012026-09-300000862668us-gaap:RetainedEarningsMember2026-07-012026-09-300000862668us-gaap:PreferredStockMember2026-09-300000862668us-gaap:CommonStockMember2026-09-300000862668us-gaap:AdditionalPaidInCapitalMember2026-09-300000862668us-gaap:RetainedEarningsMember2026-09-300000862668us-gaap:PreferredStockMember2025-06-300000862668us-gaap:CommonStockMember2025-06-300000862668us-gaap:AdditionalPaidInCapitalMember2025-06-300000862668us-gaap:RetainedEarningsMember2025-06-3000008626682025-06-300000862668us-gaap:PreferredStockMember2025-07-012025-09-300000862668us-gaap:CommonStockMember2025-07-012025-09-300000862668us-gaap:AdditionalPaidInCapitalMember2025-07-012025-09-300000862668us-gaap:RetainedEarningsMember2025-07-012025-09-300000862668us-gaap:PreferredStockMember2025-09-300000862668us-gaap:CommonStockMember2025-09-300000862668us-gaap:AdditionalPaidInCapitalMember2025-09-300000862668us-gaap:RetainedEarningsMember2025-09-3000008626682025-09-300000862668us-gaap:ConvertiblePreferredStockMember2026-07-012026-09-300000862668us-gaap:ConvertiblePreferredStockMember2025-07-012025-09-300000862668us-gaap:StockOptionMember2026-07-012026-09-300000862668us-gaap:StockOptionMember2025-07-012025-09-300000862668esmc:EconomicInjuryDisasterLoanMember2026-09-300000862668esmc:EconomicInjuryDisasterLoanMember2026-07-012026-09-300000862668us-gaap:CustomerConcentrationRiskMemberesmc:CustomerOneMember2026-07-012026-09-300000862668us-gaap:CustomerConcentrationRiskMemberesmc:CustomerOneMemberus-gaap:SalesRevenueNetMember2026-07-012026-09-300000862668us-gaap:CustomerConcentrationRiskMemberesmc:CustomerTwoMemberus-gaap:SalesRevenueNetMember2026-07-012026-09-300000862668us-gaap:CustomerConcentrationRiskMemberesmc:CustomerOneMemberus-gaap:SalesRevenueNetMember2025-07-012025-09-300000862668us-gaap:AccountsReceivableMember2026-07-012026-09-300000862668us-gaap:CustomerConcentrationRiskMemberesmc:CustomerOneMemberus-gaap:AccountsReceivableMember2026-07-012026-09-300000862668us-gaap:CustomerConcentrationRiskMemberesmc:CustomerTwoMemberus-gaap:AccountsReceivableMember2026-07-012026-09-300000862668us-gaap:AccountsReceivableMember2025-07-012025-09-300000862668us-gaap:CustomerConcentrationRiskMemberesmc:CustomerOneMemberus-gaap:AccountsReceivableMember2025-07-012026-03-310000862668us-gaap:SupplierConcentrationRiskMemberus-gaap:SalesRevenueNetMemberesmc:SupplieroneMember2025-07-012025-09-300000862668us-gaap:SupplierConcentrationRiskMemberus-gaap:SalesRevenueNetMemberesmc:SupplierTwoMember2025-07-012025-09-300000862668us-gaap:SupplierConcentrationRiskMemberus-gaap:AccountsPayableMember2026-07-012026-09-300000862668us-gaap:SupplierConcentrationRiskMemberesmc:AccountsPayableBenchmarkMemberesmc:SupplieroneMember2026-07-012026-09-300000862668us-gaap:SupplierConcentrationRiskMemberus-gaap:AccountsPayableMember2025-07-012025-12-310000862668us-gaap:SupplierConcentrationRiskMemberesmc:AccountsPayableBenchmarkMemberesmc:SupplieroneMember2025-07-012025-12-310000862668us-gaap:GeographicConcentrationRiskMembercountry:US2026-07-012026-09-300000862668us-gaap:GeographicConcentrationRiskMemberus-gaap:SalesRevenueNetMembercountry:US2026-07-012026-09-300000862668us-gaap:GeographicConcentrationRiskMembercountry:US2025-07-012025-09-300000862668us-gaap:GeographicConcentrationRiskMemberus-gaap:SalesRevenueNetMembercountry:US2025-07-012025-09-300000862668us-gaap:GeographicConcentrationRiskMemberus-gaap:NonUsMember2026-07-012026-09-300000862668us-gaap:GeographicConcentrationRiskMemberus-gaap:SalesRevenueNetMemberus-gaap:NonUsMember2026-07-012026-09-300000862668us-gaap:GeographicConcentrationRiskMemberus-gaap:NonUsMember2025-07-012025-09-300000862668us-gaap:GeographicConcentrationRiskMemberus-gaap:SalesRevenueNetMemberus-gaap:NonUsMember2025-07-012025-09-300000862668us-gaap:GeographicConcentrationRiskMember2026-07-012026-09-300000862668us-gaap:GeographicConcentrationRiskMemberus-gaap:SalesRevenueNetMember2026-07-012026-09-300000862668us-gaap:GeographicConcentrationRiskMember2025-07-012025-09-300000862668us-gaap:GeographicConcentrationRiskMemberus-gaap:SalesRevenueNetMember2025-07-012025-09-300000862668srt:MinimumMember2025-10-232025-10-230000862668srt:MaximumMember2025-10-232025-10-2300008626682025-10-2300008626682026-04-012026-06-300000862668esmc:ReportableSegmentMember2026-07-012026-09-300000862668esmc:ReportableSegmentMember2025-07-012025-09-30
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
QUARTERLY PERIOD PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
For the Quarterly Period ended September 30, 2026
Commission File Number 0-20127
Escalon Medical Corp.
(Exact name of registrant as specified in its charter)
| | | | | | | | |
| Pennsylvania | | 33-0272839 |
(State or other jurisdiction of incorporation or organization) | | (I.R.S. Employer Identification No.) |
994 Old Eagle School Road Suite 1015, Wayne, PA 19087
(Address of principal executive offices, including zip code)
(610) 688-6830
(Registrant’s telephone number, including area code)
N/A
Former name, former address and former fiscal year, if changed since last report
Securities registered pursuant to Section 12(b) of the Act: NONE
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No o
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes x No o
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company. or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," and "smaller reporting company" and "emerging growth company" in Rule 12b-2 of the Exchange Act.
| | | | | | | | | | | | | | | | | | | | |
| Large accelerated filer | | o | | Accelerated filer | | o |
| | | | | |
| Non-accelerated filer | | x | | Smaller reporting company | | x |
| | | | | | |
| | | | Emerging growth company | | o |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). o Yes x No
Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date: 7,415,329 shares of common stock, $0.001 par value outstanding as of November 13, 2026.
| | | | | | | | |
| | Page |
| PART I Financial Information | 4 |
| Item I. | Unaudited Condensed Consolidated Financial Statements | 4 |
| Condensed Consolidated Balance Sheets as of September 30, 2026 (unaudited) and June 30, 2026 | 4 |
| Condensed Consolidated Statements of Operations for the three-month periods ended September 30, 2026 and 2025 (unaudited) | 5 |
| Condensed Consolidated Statements of Stockholders' Equity for the three-month periods ended September 30, 2026 and 2025 (unaudited) | 6 |
| Condensed Consolidated Statements of Cash Flows for the three-month periods ended September, 2026 and 2025 (unaudited) | 7 |
| Notes to the Condensed Consolidated Financial Statements (Unaudited) | 9 |
| Item 2. | Management's Discussion and Analysis of Financial Condition and Results of Operations | 18 |
| Item 3. | Quantitative and Qualitative Disclosures about Market Risk | 24 |
| Item 4. | Controls and Procedures | 24 |
| | |
| PART II Other Information | |
| Item 1. | Legal Proceedings | 25 |
| Item 1A. | Risk Factors | 25 |
| Item 2. | Unregistered Sales of Equity Securities and Use of Proceeds | 25 |
| Item 3. | Defaults Upon Senior Securities | 25 |
| Item 4. | Mine Safety Disclosures | 25 |
| Item 5. | Other Information | 25 |
| Item 6. | Exhibits | 25 |
PART 1. FINANCIAL INFORMATION
Item I. UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
ESCALON MEDICAL CORP. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
| | | | | | | | | | | |
| September 30, 2026 | | June 30, 2026 |
| (Unaudited) | | |
| ASSETS | | | |
| Current assets: | | | |
| Cash | $ | 3,667,758 | | | $ | 3,065,468 | |
| | | |
| Accounts receivable | 1,986,094 | | | 1,977,254 | |
| Less: allowance for credit losses | (74,161) | | | (74,035) | |
| Accounts receivable, net | 1,911,933 | | | 1,903,219 | |
| Inventories | 1,835,489 | | | 1,733,984 | |
| Other current assets | 284,501 | | | 309,255 | |
| Total current assets | 7,699,681 | | | 7,011,926 | |
| Property and equipment, net | 23,694 | | | 26,605 | |
| Right-of-use assets | 1,094,243 | | | 827,057 | |
| License and patent, net | 8,045 | | | 8,134 | |
| Deferred income tax assets, net | 1,139,449 | | | 1,139,449 | |
| Other long term assets | 101,228 | | | 114,944 | |
| Total assets | $ | 10,066,340 | | | $ | 9,128,115 | |
| LIABILITIES AND STOCKHOLDERS’ EQUITY | | | |
| Current liabilities: | | | |
| | | |
| Current portion of EIDL loan | 3,531 | | | 3,499 | |
| Accounts payable | 1,219,333 | | | 928,562 | |
| Accrued expenses | 797,938 | | | 817,529 | |
| Current portion of operating lease liabilities | 216,743 | | | 159,351 | |
| Deferred revenue | 504,629 | | | 388,297 | |
| | | |
| Other short term liabilities | 90,770 | | | 91,254 | |
| Total current liabilities | 2,832,944 | | | 2,388,492 | |
| Operating lease liabilities, net of current portion | 901,959 | | | 676,514 | |
| EIDL loan, net of current portion | 134,461 | | | 135,376 | |
| | | |
| | | |
| Total liabilities | 3,869,364 | | | 3,200,382 | |
Commitments and Contingencies (Note 8) | | | |
| Stockholders' equity: | | | |
Series A convertible preferred stock, $0.001 par value; 2,000,000 shares authorized; 2,000,000 shares issued and outstanding (liquidation value of $1,089,996 and $1,077,131) | 645,000 | | | 645,000 | |
| Common stock, $0.001 par value; 35,000,000 shares authorized; 7,415,329 shares issued and outstanding | 7,415 | | | 7,415 | |
| Additional paid-in capital | 69,702,043 | | | 69,702,043 | |
| Accumulated deficit | (64,157,482) | | | (64,426,725) | |
| Total stockholders’ equity | 6,196,976 | | | 5,927,733 | |
| Total liabilities and stockholders’ equity | $ | 10,066,340 | | | $ | 9,128,115 | |
See notes to unaudited condensed consolidated financial statements.
| | | | | | | | | | | | | | | | | |
ESCALON MEDICAL CORP. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) |
| | | For the Three Months Ended September 30, |
| | | | | 2026 | | 2025 |
| Net revenues: | | | | | | | |
| Products | | | | | $ | 3,580,677 | | | $ | 2,536,881 | |
| Service plans | | | | | 132,935 | | | 138,440 | |
| Revenues, net | | | | | 3,713,612 | | | 2,675,321 | |
| Costs and expenses: | | | | | | | |
| Cost of revenue | | | | | 2,082,928 | | | 1,554,579 | |
| Marketing, general and administrative | | | | | 1,266,738 | | | 1,107,395 | |
| Research and development | | | | | 94,398 | | | 216,098 | |
| | | | | | | |
Total costs and expenses | | | | | 3,444,064 | | | 2,878,072 | |
| Income (loss) from operations | | | | | 269,548 | | | (202,751) | |
| Other income (expenses) | | | | | | | |
| | | | | | | |
| Other expenses | | | | | — | | | (32,797) | |
| | | | | | | |
| Interest expense, net | | | | | (305) | | | (4,304) | |
| | | | | | | |
| Net income (loss) before income tax | | | | | 269,243 | | 0 | (239,852) | |
| Income tax expense | | | | | — | | | — | |
| Net income (loss) | | | | | 269,243 | | | (239,852) | |
| Less undeclared dividends on preferred stocks | | | | | 12,865 | | | 13,006 | |
| Less income allocated to convertible preferred stocks | | | | | 120,848 | | | — | |
| Net income (loss) applicable to common stockholders | | | | | $ | 135,530 | | | $ | (252,858) | |
| Net earnings (loss) per share | | | | | | | |
| Basic earnings (loss) per share applicable to common stockholder | | | | | $ | 0.02 | | | $ | (0.03) | |
| Diluted earnings (loss) per share | | | | | $ | 0.02 | | | $ | (0.03) | |
| Weighted average shares—basic | | | | | 7,415,329 | | 7,415,329 | |
| Weighted average shares—diluted | | | | | 14,187,529 | | 7,415,329 | |
See notes to unaudited condensed consolidated financial statements.
ESCALON MEDICAL CORP. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY
FOR THE THREE MONTHS ENDED SEPTEMBER 30, 2026 AND 2025
(UNAUDITED)
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | Series A Convertible Preferred Stock | | Common Stock | | Additional Paid-in Capital | | Accumulated Deficit | | Total Stockholders’ Equity |
| | Shares | | Amount | | Shares | | Amount | | | | | | |
| Balance at June 30, 2026 | | 2,000,000 | | | $ | 645,000 | | | 7,415,329 | | | $ | 7,415 | | | $ | 69,702,043 | | | $ | (64,426,725) | | | $ | 5,927,733 | |
| Net income | | — | | | — | | | — | | | — | | | — | | | 269,243 | | | 269,243 | |
| Balance at September 30, 2026 | | 2,000,000 | | | $ | 645,000 | | | 7,415,329 | | | $ | 7,415 | | | $ | 69,702,043 | | | $ | (64,157,482) | | | $ | 6,196,976 | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | Series A Convertible Preferred Stock | | Common Stock | | Additional Paid-in Capital | | Accumulated Deficit | | Total Stockholders’ Equity |
| | Shares | | Amount | | Shares | | Amount | | | | | | |
| Balance at June 30, 2025 | | 2,000,000 | | | $ | 645,000 | | | 7,415,329 | | | $ | 7,415 | | | $ | 69,702,043 | | | $ | (68,439,351) | | | $ | 1,915,107 | |
| Net loss | | — | | | — | | | — | | | — | | | — | | | (239,852) | | (239,852) | |
| Balance at September 30, 2025 | | 2,000,000 | | | $ | 645,000 | | | 7,415,329 | | | $ | 7,415 | | | $ | 69,702,043 | | | $ | (68,679,203) | | | $ | 1,675,255 | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
See notes to unaudited condensed consolidated financial statements.
| | | | | | | | | | | |
|
ESCALON MEDICAL CORP. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) |
|
| For the Three Months Ended September 30, |
| 2026 | | 2025 |
| | | |
| Cash Flows from Operating Activities: | | | |
| Net income (loss) | $ | 269,243 | | | $ | (239,852) | |
| Adjustments to reconcile net income (loss) to net cash provided by operating activities: | | | |
| | | |
| Change in allowance for credit loss | 126 | | | (89,322) | |
| | | |
| Depreciation and amortization | 3,000 | | | 8,170 | |
| Non cash lease expense | 51,838 | | | 18,317 | |
| | | |
| | | |
| Change in operating assets and liabilities: | | | |
| Accounts receivable | (8,840) | | | 255,391 | |
| Inventories | (101,505) | | | 395,939 | |
| Other current assets | 24,754 | | | (102,666) | |
| Other long-term assets | 13,716 | | | — | |
| Accounts payable | 290,771 | | | (206,810) | |
| Accrued expenses | (19,591) | | | 113,953 | |
| Change in operating lease liability | (36,187) | | | (17,733) | |
| Deferred revenue | 116,332 | | | (50,451) | |
| Other short-term and long-term liabilities | (484) | | | 72 | |
| Net cash provided by operating activities | 603,173 | | | 85,008 | |
| Cash Flows from Investing Activities: | | | |
| | | |
| Purchase of equipment | — | | | (4,421) | |
| Net cash used in investing activities | — | | | (4,421) | |
| Cash Flows from Financing Activities: | | | |
| Repayment of note payable | — | | | (9,832) | |
| Repayment of EIDL loan | (883) | | | (767) | |
| Net cash used in financing activities | (883) | | | (10,599) | |
| Net increase in cash, cash equivalents and restricted cash | 602,290 | | | 69,988 | |
| Cash, and restricted cash, beginning of period | 3,065,468 | | | 802,385 | |
| Cash, and restricted cash, end of period | $ | 3,667,758 | | | $ | 872,373 | |
| | | |
| Cash, and restricted cash consist of the following: | | | |
| End of period | | | |
| Cash | $ | 3,667,758 | | | $ | 615,791 | |
| Restricted cash | — | | | 256,582 | |
| $ | 3,667,758 | | | $ | 872,373 | |
| Beginning of period | | | |
| Cash | $ | 3,065,468 | | | $ | 545,835 | |
| Restricted cash | — | | | 256,550 | |
| $ | 3,065,468 | | | $ | 802,385 | |
| | | |
| Supplemental Schedule of Cash Flow Information: | | | |
| Income taxes paid | $ | 15,778 | | | $ | 3,200 | |
| | | | | | | | | | | |
| Interest paid | $ | 1,310 | | | $ | 4,336 | |
| | | |
| Non Cash Finance Activities | | | |
| Non-cash ROU assets and Liability recognition | $ | 319,024 | | | $ | — | |
| | | |
| | | |
| | | |
| | | |
See notes to unaudited condensed consolidated financial statements
Escalon Medical Corp. and Subsidiaries
Notes to Unaudited Condensed Consolidated Financial Statements
1. Organization and Basis of Presentation
Escalon Medical Corp. ("Escalon" or "Company") is a Pennsylvania corporation initially incorporated in California in 1987, and reincorporated in Pennsylvania in November 2001. Within this document, the Company collectively shall mean Escalon, which includes its division called "Trek" and its wholly owned subsidiaries: Sonomed, Inc. (“Sonomed”), Escalon Digital Solutions, Inc. (“EMI”), and Sonomed IP Holdings, Inc.
The Company operates in the healthcare market, specializing in the development, manufacture, marketing and distribution of medical devices and pharmaceuticals in the area of ophthalmology. The Company and its products are subject to regulation and inspection by the United States Food and Drug Administration (the “FDA”). The FDA and other government authorities require extensive testing of new products prior to sale and have jurisdiction over the safety, efficacy and manufacture of products, as well as product labeling and marketing.
The accompanying unaudited condensed consolidated financial statements (“financial statements”) have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) and have been consistently applied. Certain information and footnote disclosures normally included in financial statements presented in accordance with GAAP, but which are not required for interim reporting purposes, have been omitted. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary to present fairly the financial position as of September 30, 2026, and the results of operations and cash flows for the interim periods ended September 30, 2026, and 2025, have been included. These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto for the year ended June 30, 2026 included in the Company’s Annual Report on Form 10-K, as filed with the Securities and Exchange Commission on October 13, 2026. Operating results for the three months ended September 30, 2026 are not necessarily indicative of the results that may be expected for the full year ending June 30, 2027.
The Company’s common stock trades on the OTCQB Market under the symbol “ESMC.”
2. Summary of Significant Accounting Policies
Principles of Consolidation
The condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany accounts and transactions have been eliminated.
Use of Estimates
The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America ("US GAAP") requires management to make estimates and assumptions that impact the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.
Segment Information
The Company has one operating and reportable segment. The Company’s Chief Operating Decision Maker (CODM) is its Chief Executive Officer and Chief Operating Officer, who reviews financial information presented on a consolidated basis for the purpose of allocating resources and evaluating financial performance.
Accounts Receivable
Accounts receivables are recorded at net realizable value. The Company performs ongoing credit evaluations of customers financial conditions and does not require collateral for accounts receivable arising in the normal course of business. The Company maintains allowances for potential credit losses based on the Company’s historical trends, specific customer issues and current economic trends. Accounts are written off against the allowance when they are determined to be uncollectible based on management’s assessment of individual accounts. While such credit losses have historically been within the Company’s expectation and the provision established, the Company cannot guarantee about the amount of future credit losses or the
sufficiency of the allowance therefore. The Company recorded an allowance for credit losses of $74,161 and $74,035 as of September 30, 2026 and June 30, 2026, respectively.
The activity for the allowance for credit losses during three months and three months ended September 30, 2026 and 2025, is as follows
| | | | | | | | | | | | | | | | | |
| | | | | | | |
| | | For the Three Months Ended September 30, |
| | | | | 2026 | | 2025 |
| Balance, at beginning of the period | | | | | $ | 74,035 | | | $ | 164,499 | |
| Provision | | | | | 126 | | | — | |
| Recovery | | | | | — | | | (88,134) | |
| Write-offs | | | | | — | | | (1,188) | |
| Balance, at the end of the period | | | | | $ | 74,161 | | | $ | 75,177 | |
Inventories
Inventories are stated at the lower of cost or net realizable value. Cost is determined on a first-in, first-out basis and include freight-in materials, labor and overhead costs. Inventories are written down if the estimated net realizable value is less than the recorded value. The Company reviews the carrying cost of inventories by product to determine the adequacy of reserves for obsolescence. In accounting for inventories, the Company must make estimates regarding the estimated realizable value of inventory. The estimate is based, in part, on age of inventory. If actual conditions are less favorable than those the Company has projected, the Company may need to increase its reserves for excess and obsolete inventories. Any increases in the reserves will adversely impact the Company’s results of operations. The establishment of a reserve for excess and obsolete inventory establishes a new cost basis in the inventory. Such reserves are not reduced until the product is sold. If the Company is able to sell such inventory any related reserves would be reversed in the period of sale. In accordance with industry practice, service parts inventory is included in current assets, although service parts are carried for established requirements during the serviceable lives of the products and, therefore, not all parts are expected to be sold within one year.
Deferred Revenue
The Company records deferred revenue when payments are received or become due in advance of the Company's performance of its obligations under the contract. Deferred revenue primarily consists of customer deposits and advance payments, amounts received for customer care plans covering a 12-month service period, and amounts allocated to software installation and training services associated with equipment sales for which the Company has not yet fulfilled its performance obligations. Revenue related to customer care plans is recognized over the service period, while revenue related to software installation and training services is recognized upon completion of the respective services. The consideration received is recognized monthly over the service period. Revenue recorded that was included within prior period deferred revenue was $282,000 and $133,000, respectively for the three-month periods ended September 30, 2026 and 2025.
| | | | | | | | | | | | | | | | | | |
| (in thousands) | | | | Three Months ended September 30, |
| | | | | | 2026 | | 2025 |
| Beginning of Period | | | | | | $ | 388 | | | $ | 328 | |
| Additions | | | | | | 437 | | | 111 | |
| Revenue Recognized | | | | | | (320) | | | (162) | |
| End of Period | | | | | | $ | 505 | | | $ | 277 | |
Earnings Per Share
The Company used the two-class method to compute net income per common share. These participating securities included the Company’s convertible preferred stock which accrues dividends payable. The two-class method requires earnings for the period to be allocated between common stock and participating securities based upon their respective rights to receive distributed and undistributed earnings.
Under the two-class method, for periods with net income, basic net income per common share is computed by dividing the net income attributable to common stockholders by the weighted average number of shares of common stock outstanding during the period. Net income attributable to common stockholders is computed by subtracting from net income the portion of current period earnings that the participating securities would have been entitled to receive pursuant to their dividend rights had all of the period’s earnings been distributed. No such adjustment to earnings is made during periods with a net loss, as the holders of the participating securities have no obligation to fund losses.
Diluted net income per common share is computed under the two-class method by using the weighted average number of shares of common stock outstanding, plus, for periods with net income attributable to common stockholders, the potential dilutive effects of stock options. The Company analyzed the potential dilutive effect of any outstanding dilutive securities under the “if-converted” method and treasury-stock method when calculating diluted earnings per share, in which it is assumed that the outstanding participating securities convert into common stock at the beginning of the period or date of issuance, if later. The Company reports the more dilutive of the approaches (two-class or “if-converted”) as its diluted net income per share during the period. Basic earning per share is computed by dividing net income by the weighted average number of shares of common stock outstanding during the period. There was no stock options as of September 30, 2026. As of September 30, 2025, the average market prices for the three months then ended are less than the exercise price of all the outstanding stock options and, therefore, the inclusion of the stock options would be anti-dilutive.
| | | | | | | | | | | | | | | | | |
| | | For the Three Months Ended September 30, |
| | | | | 2026 | | 2025 |
| Numerator: | | | | | | | |
| Numerator for basic income per share: | | | | | | | |
| Net income (loss) | | | | | $ | 269,243 | | | $ | (239,852) | |
| Less undeclared dividends on convertible stocks | | | | | 12,865 | | | 13,006 | |
| Less net income allocated to convertible preferred stocks | | | | | 120,848 | | | — | |
| Net income applicable to common stockholders | | | | | $ | 135,530 | | | $ | (252,858) | |
| Numerator for diluted earnings per share: | | | | | | | |
| | | | | | | |
| Net income (loss) | | | | | $ | 269,243 | | | $ | (239,852) | |
| Less: Undeclared dividends on convertible stocks | | | | | 12,865 | | | 13,006 | |
| Diluted income | | | | | $ | 256,378 | | | $ | (252,858) | |
| | | | | | | |
| Denominator: | | | | | | | |
| Denominator for basic income per share - weighted average shares outstanding | | | | | 7,415,329 | | | 7,415,329 | |
| Weighted average preferred stock converted to common stock | | | | | 6,772,200 | | | — | |
| Denominator for diluted earnings per share - weighted average and assumed conversion | | | | | 14,187,529 | | | 7,415,329 | |
| | | | | | | |
| Net earnings per share: | | | | | | | |
| Basic net earnings per share | | | | | $ | 0.02 | | | $ | (0.03) | |
| Diluted net earnings per share | | | | | $ | 0.02 | | | $ | (0.03) | |
| | | | | | | |
| | | | | | | |
The following table summarizes convertible securities that, if exercised would have an anti-dilutive effect on earnings per share.
| | | | | | | | | | | | | | | | | |
| | | For the Three Months Ended September 30, |
| | | | | 2026 | | 2025 |
| Stock options | | | | | — | | 21,000 |
| Convertible preferred stock | | | | | — | | 6,923,580 |
| Total potential dilutive securities not included in income per share | | | | | — | | 6,944,580 |
Income Taxes
The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the condensed consolidated financial statements. Under this method, the Company determines deferred tax assets and liabilities on the basis of the differences between the financial statement and tax bases of assets and liabilities by using enacted tax rates in effect for the period in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date. The estimated annual effective tax rate is updated quarterly based on changes in the forecast of full-year income and tax expense. For the three months and three months ended September 30, 2026 and 2025, the Company’s provision for income taxes and effective tax rate were zero.
The Company recognizes deferred tax assets to the extent that it believes that these assets are more likely than not to be realized. In making such a determination, the Company considers all available positive and negative evidence, including its cumulative income in recent years and projected future taxable income. If the Company determines that it would be able to realize its deferred tax assets in the future in excess of their net recorded amount, the Company would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income taxes. A release of the valuation allowance would result in the recognition of certain deferred tax assets and a corresponding income tax benefit in the period the release is recorded. The amount of the valuation allowance release will be determined based on the available sources of future taxable income as of the period in which the release is recorded. The Company released $1,139,449 of its valuation allowance related to previously unrecognized deferred tax assets and recognized a corresponding deferred income tax benefit in the consolidated statement of operations for the fiscal year ended June 30, 2026. As of September 30, 2026 and June 30, 2026, the remaining valuation allowance against its deferred tax assets was $5,393,142. The Company continues to assess the realizability of its deferred tax assets each reporting period and maintains a valuation allowance against deferred tax assets that are not considered more likely than not to be realized. Any further release of the valuation allowance would result in an additional income tax benefit in the period the release is recorded. The amount of any valuation allowance release will be determined based on the available sources of future taxable income as of the period in which the release is recorded. The Company will continue to evaluate its deferred tax assets and the related valuation allowance each reporting period.
The Company records uncertain tax positions in accordance with ASC 740 on the basis of a two-step process in which (1) the Company determines whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the position and (2) for those tax positions that meet the more-likely-than-not recognition threshold, the Company recognizes the largest amount of tax benefit that is more than 50 percent likely to be realized upon ultimate settlement with the related tax authority.
The Company recognizes interest and penalties related to unrecognized tax benefits on the income tax expense line in the accompanying unaudited condensed consolidated statements of operations. As of September 30, 2026 and June 30, 2026, no accrued interest or penalties were required to be included on the related tax liability line in the condensed consolidated balance sheets.
Leases
The Company determines if an arrangement is a lease at the inception of a contract. Operating lease right-of-use ("ROU") assets are included in right-of-use assets on the consolidated balance sheets. The current and long-term components of operating lease liabilities are included in the current portion of operating lease liabilities and operating lease liabilities, net of current portion, respectively on the consolidated balance sheets.
Operating lease ROU assets and operating lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term. As most of the Company's leases do not provide an implicit rate, the Company uses an incremental borrowing rate based on the information available at the commencement date in determining the present value of future payments. Certain leases may include options to extend or terminate the lease. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term.
Recent Accounting Pronouncements Not Yet Adopted
In November 2024, FASB issued ASU 2024-03, Income Statement reporting Comprehensive Income - Expense Disaggregation Disclosure (Subtopic 220-40): Disaggregation of Income Statement Expense. As subsequently amended by ASU 2025-01 the standard requires disclosure in the notes to the financial statements of specified information about certain costs and expenses. The amendments are effective for the fiscal years beginning after December 15, 2026, and for interim periods within the fiscal years beginning after December 15, 2027. Early adoption is permitted. The amendments should be applied either prospectively to financial statements issued for reporting periods after the effective date of this ASU or retrospectively to any or all prior
periods presented in the financial statements. The Company is currently evaluating the new guidance to determine the impact it may have on its consolidated financial statements and related disclosure.
In December 2025, the FASB issued ASU 2025-12, Codification Improvements. The amendments address various technical corrections, clarifications, and other improvements to the FASB Accounting Standards Codification. The amendments are effective for annual reporting periods beginning after December 15, 2026, including interim periods within those annual reporting periods. The Company is currently evaluating the impact of this ASU on its consolidated financial statements and related disclosures.
In April 2026, the FASB issued ASU 2026-01, Equity (Topic 505): Initial Measurement of Paid-in-Kind Dividends on Equity-Classified Preferred Stock. The amendments provide guidance on the initial measurement of paid-in-kind dividends on equity-classified preferred stock. The amendments are effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods within those annual reporting periods. Early adoption is permitted. The Company is currently evaluating the applicability and potential impact of this ASU on its consolidated financial statements and related disclosures.
3. Inventories
| | | | | | | | | | | |
| September 30, | | June 30, |
| (in thousands) | 2026 | | 2026 |
| Inventories: | | | |
| Raw Material | $ | 982 | | | $ | 997 | |
| Work-In-Process | 123 | | | 60 | |
| Finished Goods | 730 | | | 677 | |
| Total inventories | $ | 1,835 | | | $ | 1,734 | |
| | | |
4. Related Party Transactions and Preferred Stock
On February 14, 2018, the Company entered into a Debt Exchange Agreement (the “Exchange Agreement”) with Mr. DePiano Sr., the Company's former Chairman and DP Associates Inc. Profit-Sharing Plan of which Mr. DePiano Sr. was the sole owner and sole trustee (the “Holders”). Pursuant to the terms of the Exchange Agreement, effective February 15, 2018, the Holders exchanged a total of $645,000 principal amount of debt related to the accounts receivable factoring program for 2,000,000 shares of Series A Convertible Preferred Stock (the “Preferred Stock”).
Each share of Preferred Stock entitles the Holder thereof to 13 votes per share and will vote together with all other classes and series of stock of the Company as a single class on all actions to be taken by the Company’s stockholders. As a result of this voting power, the Holders as of September 30, 2026 beneficially own approximately 77.81% of the voting power on all actions to be taken by the Company’s stockholders.
Subject to the terms and conditions of Preferred Stock, the holder of any share or shares of the Preferred Stock has the right, at its option at any time, to convert each such share of Preferred Stock (except that, upon any liquidation of the Company, the right of conversion will terminate at the close of business on the business day fixed for payment of the amounts distributable on the Preferred Stock) into 2.15 shares of Common Stock (the “Conversion Ratio”). The Conversion Ratio is subject to standard provisions for adjustment in the event of a subdivision or combination of the Company’s Common Stock and upon any reorganization or reclassification of the capital stock of the Company. If the Holders were to convert their shares of Preferred Stock into Common Stock at the Conversion Ratio the Holders would receive a total of 4,300,000 shares of Common Stock, or approximately 36.70% of the then outstanding shares of Common Stock assuming such conversion.
Each outstanding share of the Preferred Stock accrues dividends calculated cumulatively at the annual rate of $.0258 per share (such amount subject to equitable adjustment in the event of any stock dividend, stock split, combination, reclassification other similar event), payable upon the earlier of (i) a liquidation, dissolution or winding up of the Company or (ii) conversion of the Preferred Stock into Common Stock. Upon either of such events, all such accrued and unpaid dividends, whether or not earned or declared, to and until the date of such event, will become immediately due and payable and will be paid in full. The dividends payable to the holders of the Preferred Stock are payable in cash or, at the election of any such holder, in a number of additional shares of Common Stock equal to the amount of the dividend expressed in dollars divided by the then applicable Conversion Ratio, described above. As of September 30, 2026 and June 30, 2026 the cumulative dividends payable are $444,996 ($0.2225 per share) and $432,131 ($0.2161 per share), respectively.
The weighted-average number of common shares was calculated by including the common shares issuable upon conversion of cumulative dividends payable on the convertible preferred stock, with the number of additional common shares determined in accordance with the applicable conversion provisions of the preferred stock, including the applicable Conversion Ratio.
The weighted average preferred stock converted to common stock represents the aggregate of 4,300,000 shares issuable upon conversion of the 2,000,000 convertible preferred stock and additional common shares issuable upon conversion of cumulative accrued dividends payable, calculated using the quarter-end stock price. As of September 30, 2026 and 2025, the weighted average preferred stock converted to common stock balance was 6,772,200 and 0, respectively.
After Mr. DePiano Sr. passed away on October 3, 2019, the abovementioned shares of Preferred Stock are now held in Richard DePiano Sr Trust under the Will (TUW) with Mr. DePiano, Jr. as the trustee.
5. Long-term debt
Economic Injury Disaster Loan ("EIDL")
EIDL is designed to provide economic relief to businesses that are currently experiencing a temporary loss of revenue due to the Coronavirus (COVID-19) pandemic. EIDL proceeds can be used to cover a wide array of working capital and normal operating expenses, such as continuation to health care benefits, rent, utilities, and fixed debt payments. The Company received $150,000 EIDL loan. The annual interest rate is 3.75%. The payment term is 30 years and the monthly payment is $731 from July 1, 2021. The EIDL loan is secured by the tangible and intangible personal property of the Company.
The future annual principal amounts to be paid as of September 30, 2026 are as follows:
| | | | | |
| |
| Year ending June 30, | EIDL Loan Payment |
| |
| 2027 (remaining of FY 2027) | $ | 2,636 | |
| 2028 | 3,632 | |
| 2029 | 3,771 | |
| 2030 | 3,914 | |
| 2031 | 4,064 | |
| Thereafter | 119,975 | |
| Total | $ | 137,992 | |
| |
6. Concentration of Credit Risk
Credit Risk
Financial Instruments, which potentially subject the Company to concentration of credit risk, consist principally of cash and cash equivalents, restricted cash and trade receivables. Concentration of credit risk with respect to trade receivables is generally diversified due to the large number of entities comprising the Company's customer base and their dispersion across geographic areas principally within the United States and international. The Company routinely addresses the financial strength of its customers and, as a consequence, believes that its receivable credit risk exposure is limited. The Company does not require customers to post collateral.
Major Customer
Two customers accounted for 13% and 11% of net sales during the three months ended September 30, 2026. One customer accounted for approximately 17% of net sales during the three months ended September 30, 2025.
As of September 30, 2026, the Company had two customers that represented approximately 20% and 13% of the total accounts receivable balance. As of June 30, 2026, the Company had one customer that represents approximately 17% of the total accounts receivable balance.
Major Supplier
The Company's two largest suppliers accounted for 46% and 13% of the total purchases for the three months ended September 30, 2026. The Company's two largest suppliers accounted for 30% and 22% of total purchases for the three months ended September 30, 2025.
As of September 30, 2026, the Company had one supplier that represented approximately 53% of the total accounts payable balance. As of June 30, 2026, the Company had one supplier that represented 44% of the total accounts payable balance.
Foreign Sales
Domestic and international sales from continuing operations are as follows:
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| (in thousands) | | | For the Three Months Ended September 30, |
| | | | | 2026 | | 2025 |
| Domestic | | | | | | | | | $ | 1,968 | | | 53.0 | % | | $ | 1,626 | | | 60.8 | % |
| Foreign | | | | | | | | | 1,745 | | | 47.0 | % | | 1,049 | | | 39.2 | % |
| Total | | | | | | | | | $ | 3,713 | | | 100.0 | % | | $ | 2,675 | | | 100.0 | % |
7. Leases
Lessee Arrangements
The Company leases certain facilities and equipment under operating leases and leases that meet the definition of a short term lease, as defined in ASC 842. The Company has elected not to apply the recognition requirements of ASC 842, for short term leases, as the term is 12 months or less.
The Company entered into a Short-Form Lease Agreement (the "Lease") with HP BC Eagle One LLC ("Landlord") for approximately 3012 rentable square feet of office space located at 994 Old Eagle School Road, Wayne, Pennsylvania, to serve as the Company's corporate office. The lease started in early July 2026, and has monthly payments ranging from $6,024 to $6,983, and the discount rate for the lease was 7.49%, equivalent to WSJ prime rate adjusted by 0.74% margin, consistent with the borrowing terms under the Company's TD loan agreement. The Company recognized a right of use asset and a lease liability of $319,024.
Total lease expense, under ASC 842, was included in cost of revenue and marketing, general and administrative costs in the Company's unaudited condensed consolidated statement of operations for the three months ended September 30, 2026, and 2025 as follows:
| | | | | | | | | | | | | | | | | |
| | | | Three Months ended September 30, | |
| | | | | 2026 | 2025 | |
| Operating lease costs: | | | | | | | |
| Fixed | | | | | $ | 77,003 | | $ | 24,157 | | |
| Total: | | | | | $ | 77,003 | | $ | 24,157 | | |
Supplemental cash flow information was as follows:
| | | | | | | | | | | | | |
| | | Three Months ended September 30, |
| | | | 2026 | 2025 |
| Cash paid for amounts included in the measurement of lease liabilities | | | | | |
| Operating cash flows for operating leases | | | | $ | 73,401 | | $ | 23,573 | |
| Total | | | | $ | 73,401 | | $ | 23,573 | |
The table below reconciles the undiscounted future minimum lease payments (displayed by year and in the aggregate) under noncancelable operating leases with terms of more than one year to the total operating lease liabilities recognized on the unaudited condensed consolidated balance sheets as of September 30, 2026:
The aggregate future lease payments for operating leases as of September 30, 2026 were as follows: | | | | | | | | |
| | Operating |
| | |
| 2027 (remaining of FY 2027) | | $ | 223,112 | |
| 2028 | | 289,918 | |
| 2029 | | 221,947 | |
| 2030 | | 226,425 | |
| 2031 | | 224,496 | |
| Thereafter | | 211,029 | |
| Total lease payments | | $ | 1,396,927 | |
| Less interest | | 278,225 | |
| Present value of lease liabilities | | $ | 1,118,702 | |
Average lease terms and discount rates were as follows:
| | | | | | | | | | | | | | |
| | September 30, 2026 | | June 30, 2026 |
| Weighted-average remaining lease terms (years) | | | | |
Operating leases | | 5.25 | | 5.57 |
| Weighted-average discount rate | | | | |
Operating leases | | 8.94 | % | | 9.47 | % |
Lessor Arrangement
During the year ended June 30, 2026, the Company entered into one sales-type lease. The net investment in the sales-type lease was and $26,312 and $29,470 as of September 30, 2026 and June 30, 2026, respectively. These amounts are classified as short-term other assets and long-term other assets in the accompanying consolidated balance sheets. For the three months ended September 30, 2026, the Company recognized interest income of $1,005 and selling profit of $1,092 related to the sales-type lease. No interest income and selling profit related to the sales-type lease was recognized for the three months ended September 30, 2025. Interest income is recognized over the lease term using the effective interest method. Selling profit, if applicable, is recognized at lease commencement when the criteria for sales-type lease accounting are met.
8. Commitments and Contingencies
Legal Proceedings
The Company, from time to time is involved in various legal proceedings and disputes that arise in the normal course of business. These matters have included intellectual property disputes, contract disputes, employment disputes and other matters. The Company does not believe that the resolution of any of these matters has had or is likely to have a material adverse impact on the Company’s business, financial condition or results of operations.
9. Segment Information
Operating segments are defined as components of an entity for which separate financial information is available and that is regularly provided to the Chief Operating Decision Maker ("CODM") in deciding how to allocate resources to an individual segment and in assessing performance.
The Company’s CODM consists of the Chief Executive Officer and Chief Operating Officer. The CODM reviews financial information presented on a consolidated basis for purposes of making operating decisions, allocating resources, and evaluating financial performance. The accounting policies of the Company’s reportable segment, as well as how the Company derives revenue, are consistent with those described in "Note 2-Basis of Presentation and Summary of Significant Accounting Policies” within these financial statements.
The CODM uses consolidated net income (loss), consistent with GAAP to assess performance, evaluate cost optimization, and allocate resources, including personnel-related and financial or capital resources, in the annual budget and forecasting process, as well as budget-to-actual variances on a monthly basis. As such, the Company has determined that it operates as one operating and reportable segment.
As the Company has only one reportable segment, all revenues, expenses, and operating results are attributable to that segment. Total assets attributable to the Company’s sole reportable segment were $10,066,340 and $9,128,115 as of September 30, 2026, and June 30, 2026.
The following tables set forth significant expense categories and other specified amounts included in consolidated net income that are otherwise regularly provided to the CODM for the three months and three months ended September 30, 2026, and 2025:
| | | | | | | | | | | | | | | | | |
| | | Three Months ended September 30, |
| | | | | 2026 | | 2025 |
| Revenue | | | | | $ | 3,713,486 | | | $ | 2,675,321 | |
| Cost of Revenue (1) | | | | | (2,082,272) | | | (1,548,540) | |
| Research and Development | | | | | (94,398) | | | (216,098) | |
| Sales and Marketing | | | | | (348,267) | | | (310,526) | |
| General and Administrative (1)(2) | | | | | (915,875) | | | (882,871) | |
| Depreciation and Amortization | | | | | (3,000) | | | (8,171) | |
| Credit loss Adjustment | | | | | (126) | | | 88,134 | |
| Other expenses | | | | | — | | | (32,797) | |
| | | | | | | |
| Interest expense, net | | | | | (305) | | | (4,304) | |
| Segment net income | | | | | $ | 269,243 | | | $ | (239,852) | |
(1) excluding depreciation and amortization expenses in cost of revenue, general and administrative expenses.
(2) excluding the credit loss adjustment.
10. Subsequent Event
Subsequent to September 30, 2026, the Company implemented a cash management strategy designed to invest excess cash while maintaining liquidity and preserving capital. In connection with this strategy, the Company invested approximately $1,180,000 in short-term US. Treasury bonds and Corporate securities and $297,000 in U.S. Treasury bonds with original maturities of three months as part of this strategy. The investment was funded with cash on hand.
ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
Forward Looking Statements
Certain statements contained in, or incorporated by reference in, this Quarterly Report on Form 10-Q are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, which provide current expectations or forecasts of future events. Such statements can be identified by the use of terminology such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “forecast,” “intend,” “may,” “plan,” “possible,” “project,” “should,” “will,” and similar words or expressions. The Company's forward-looking statements include certain information relating to general business strategy, growth strategies, financial results, liquidity, the Company's ability to continue as a going concern, discontinued operations, research and development, product development, the introduction of new products, the potential markets and uses for the Company's products, the Company's ability to increase its sales campaign effectively, the Company's regulatory filings with the FDA, acquisitions, dispositions, the development of joint venture opportunities, intellectual property and patent protection and infringement, the loss of revenue due to the expiration or termination of certain agreements, the effect of competition on the structure of the markets in which the Company competes, increased legal, accounting and Sarbanes-Oxley compliance costs, information security, cybersecurity and data privacy risks, defending the Company in litigation matters and the Company's cost saving initiatives. The reader must carefully consider forward-looking statements and understand that
such statements involve a variety of risks and uncertainties, known and unknown, and may be affected by assumptions that fail to materialize as anticipated, including risks related to inflation and tariffs, the ability to continue as a going concern including the ability to raise capital, manage operations and pursue business partnerships and cost-cutting measures, and the other risks described in the Company's Form 10-K for the fiscal year ended June 30, 2026. Consequently, no forward-looking statement can be guaranteed, and actual results may vary materially. It is not possible to foresee or identify all factors affecting the Company's forward-looking statements, and the reader therefore should not consider the list of such factors contained in its periodic report on Form 10-K for the year ended June 30, 2026 and this Form 10-Q quarterly report to be an exhaustive statement of all risks, uncertainties or potentially inaccurate assumptions.
Executive Overview—three-month periods ended September 30, 2026 and 2025
The following highlights are discussed in further detail within this Form 10-Q. The reader is encouraged to read this Form 10-Q in its entirety to gain a more complete understanding of factors impacting Company performance and financial condition.
•Consolidated net revenue increased approximately $1,038,000 or 38.8%, to $3,713,000 during the three months ended September 30, 2026, as compared to the same period of last fiscal year. The increase in net revenue is mainly attributed to a $1,070,000 increase in sales of Sonomed products, and a $76,000 increase in sales of Trek products offset by a $108,000 decrease in Digital AXIS revenue during the three months ended September 30, 2026.
•Consolidated cost of revenue totaled approximately $2,083,000, or 56.1%, of total revenue during the three months ended September 30, 2026, as compared to $1,555,000, or 58.1%, of total revenue of the same period of last fiscal year. The decrease of 2.0% in cost of revenue as a percentage of total revenue is mainly due to change in product mix and proportion of sales across different sales territories.
•Consolidated marketing, general and administrative expenses increased $160,000, or 14.5%, to $1,267,000 during the three months ended September 30, 2026, as compared to the same period of last fiscal year. The increase was primarily driven by higher sales commission and other sales and marketing expenses, increased accounting costs, business taxes, and compensation expenses during the three months ended September 30, 2026. In addition, the $88,000 reversal in credit loss expense during the three months ended September 30, 2025 contributed to the period-over-period increase.
•Consolidated research and development expenses decreased $122,000 or 56.5%, to $94,000 during the three months ended September 30, 2026, as compared to the same period of the prior fiscal year. Research and development expenses were primarily expenses associated with the introduction of new or enhanced products. The decrease in research and development expense is mainly due to a $133,000 discontinued R&D expenses following the sales of AXIS software during the three months ended September 30, 2026, offset by an increase of $11,000 ultrasound R&D expenses associated with feature enhancements.
Company Overview
The following discussion should be read in conjunction with the interim unaudited condensed consolidated financial statements and the notes thereto, which are set forth in Item 1 of this report.
The Company operates in the healthcare market specializing in the development, manufacture, marketing and distribution of medical devices and pharmaceuticals in the area of ophthalmology. The Company and its products are subject to regulation and inspection by the FDA. The FDA requires extensive testing of new products prior to sale and has jurisdiction over the safety, efficacy and manufacture of products, as well as product labeling and marketing. The Company's Internet address is www.escalonmed.com. Under the trade name of Sonomed-Escalon the Company develops, manufactures and markets ultrasound systems used for diagnosis or biometric applications in ophthalmology, develops, manufactures and distributes ophthalmic surgical products under the Trek Medical Products name, and manufactures and markets digital camera systems for ophthalmic fundus photography and image management systems.
Critical Accounting Estimates
The preparation of unaudited condensed consolidated financial statements requires management to make estimates and assumptions that impact amounts reported therein. On a regular basis, we evaluate these estimates. These estimates are based on management’s historical industry experience and on various other assumptions that are believed to be reasonable under the circumstances. Actual results may differ from these estimates.
We consider an accounting estimate to be critical if: (i) the accounting estimate requires us to make assumptions about matters that were highly uncertain at the time the accounting estimate was made, and (ii) changes in the estimate that are reasonably likely to occur from period to period or use of different estimates that we reasonably could have used in the current period, would have a material impact on our financial condition or results of operations. There are items within our financial statements that require estimation but are not deemed critical as defined above except for the estimated valuation allowance against the deferred tax asset. The company records a valuation allowance against the deferred tax asset when it is more likely than not that some portion of the deferred tax assets will not be realized. Determining the appropriate valuation allowance requires significant judgment regarding future taxable income, reversal patters of temporary differences, available tax planning strategies, and the utilization of net operating loss carryforwards.
Our significant accounting policies are more fully described in Note 2—Summary of Significant Accounting Policies to our unaudited condensed consolidated financial statements included in this report.
Results of Operations
Three Months Ended September 30, 2026 and 2025
The following table shows consolidated net revenue, as well as identifying trends in revenues for the three months ended September 30, 2026 and 2025. Table amounts are in thousands:
| | | | | | | | | | | | | | | | | | | | | | | | | |
| | | For the Three Months Ended September 30, |
| | | | | | | 2026 | | 2025 | | % Change |
| Net Revenue: | | | | | | | | | | | |
| Products | | | | | | | $ | 3,580 | | | $ | 2,537 | | | 41.1 | % |
| Service plans | | | | | | | 133 | | | 138 | | | (3.6) | % |
| Total | | | | | | | $ | 3,713 | | | $ | 2,675 | | | 38.8 | % |
Consolidated net revenue increased approximately $1,038,000 or 38.8%, to $3,713,000 during the three months ended September 30, 2026, as compared to the same period of last fiscal year. The increase in net revenue is mainly attributed to a $1,070,000 increase in sales of Sonomed products, and a $76,000 increase in sales of Trek products offset by a $108,000 decrease in Digital AXIS revenue during the three months ended September 30, 2026.
The following table presents domestic and international sales from continuing operations for the three months ended September 30, 2026 and 2025. Table amounts are in thousands:
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | For the Three Months Ended September 30, |
| | | | | 2026 | | 2025 |
| Domestic | | | | | | | | | $ | 1,968 | | | 53.0 | % | | $ | 1,626 | | | 60.8 | % |
| Foreign | | | | | | | | | 1,745 | | | 47.0 | % | | 1,049 | | | 39.2 | % |
| Total | | | | | | | | | $ | 3,713 | | | 100.0 | % | | $ | 2,675 | | | 100.0 | % |
The following table presents consolidated cost of revenue and as a percentage of revenues for the three months ended September 30, 2026 and 2025. Table amounts are in thousands:
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | For the Three Months Ended September 30, |
| | | | | | | | | 2026 | | % | | 2025 | | % |
| Cost of Revenue: | | | | | | | | | | | | | | | |
| | | | | | | | | $ | 2,083 | | | 56.1 | % | | $ | 1,555 | | | 58.1 | % |
| Total | | | | | | | | | $ | 2,083 | | | 56.1 | % | | $ | 1,555 | | | 58.1 | % |
Consolidated cost of revenue totaled approximately $2,083,000, or 56.1%, of total revenue during the three months ended September 30, 2026, as compared to $1,555,000, or 58.1%, of total revenue same period of last fiscal year. The decrease of 2.0% in cost of revenue as a percentage of total revenue is mainly due to change in product mix and proportion of sales across different sales territories.
The following table presents consolidated marketing, general and administrative expenses for the three months ended September 30, 2026 and 2025. Table amounts are in thousands:
| | | | | | | | | | | | | | | | | | | | | | | | | |
| | | For the Three Months Ended September 30, |
| | | | | | | 2026 | | 2025 | | % Change |
| Marketing, General and Administrative: | | | | | | | | | | | |
| | | | | | | $ | 1,267 | | | $ | 1,107 | | | 14.5 | % |
| Total | | | | | | | $ | 1,267 | | | $ | 1,107 | | | 14.5 | % |
Consolidated marketing, general and administrative expenses increased $160,000, or 14.5%, to $1,267,000 during the three months ended September 30, 2026, as compared to the same period of last fiscal year. The increase was primarily driven by higher sales commission and other sales and marketing expenses, increased accounting costs, business taxes, and
compensation expenses during the three months ended September 30, 2026. In addition, the $88,000 reversal in credit loss expense during the three months ended September 30, 2025 contributed to the period-over-period increase.
The following table presents consolidated research and development expenses for the three months ended September 30, 2026 and 2025.
Table amounts are in thousands:
| | | | | | | | | | | | | | | | | | | | | | | | | |
| | | For the Three Months Ended September 30, |
| | | | | | | 2026 | | 2025 | | % Change |
| Research and Development: | | | | | | | | | | | |
| | | | | | | $ | 94 | | | $ | 216 | | | (56.5) | % |
| Total | | | | | | | $ | 94 | | | $ | 216 | | | (56.5) | % |
Consolidated research and development expenses decreased $122,000, or 56.5%, to $94,000 during the three months ended September 30, 2026, as compared to same period of last fiscal year. Research and development expenses were primarily expenses associated with the introduction of new or enhanced products. The decrease in research and development expense is mainly due to a $133,000 discontinued AXIS R&D expenses following the sales of AXIS software during the three months ended September 30, 2026, offset by an increase of $11,000 ultrasound R&D expenses associated with feature enhancements.
Recently Announced Tariffs and Trade Measures
Beginning in the third quarter of fiscal year 2025, the U.S. government announced new tariffs on a broad range of imports, including a 10% tariff on most imports and additional individualized higher tariffs on certain specific goods and countries. In response, certain affected countries have imposed or may impose retaliatory tariffs on U.S. exports and may implement additional trade restrictions and/or other retaliatory measures in the future.
These recent and potential future tariffs and trade measures could adversely affect the Company’s business in several ways. Increased costs of imported raw materials, components, and finished goods may negatively impact profitability and gross margins. The Company may face challenges in passing these increased costs on to its customers due to competitive pressures or market conditions. Additionally, the uncertainty surrounding the duration and extent of these tariffs, as well as potential trade policy changes, could disrupt the Company’s supply chain, require alternative and potentially more expensive sourcing options, and impact long-term strategic planning and investment decisions. The imposition of retaliatory tariffs by other countries could also reduce the demand for the Company’s exported products, negatively impacting revenue and international sales.
Management is actively monitoring these developments, assessing the potential impacts on the Company’s business, and evaluating possible mitigation strategies, including exploring alternative sourcing, adjusting pricing strategies where feasible, and analyzing potential shifts in global supply chains. However, the ultimate financial impact of these tariffs and the associated uncertainty cannot be reasonably estimated at this time. This situation could have a material adverse effect on the Company’s future financial condition, results of operations, and cash flows. The Company will continue to evaluate these developments and provide updates in future filings as the situation evolves and more information becomes available.
Liquidity and Capital Resources
Our total cash as of September 30, 2026 was approximately $3,668,000 of cash on hand compared to approximately $3,065,000 of cash on hand as of June 30, 2026. The Company is seeking to enhance deposit insurance coverage while investing excess cash in a short-term investment portfolio designed to balance yield, liquidity, and capital preservation. Subsequent to quarter-end, the Company invested $1,180,000 in short-term investments and $297,000 in a cash equivalent.
Based on its current cash position, anticipated operating cash requirements, and planned investment strategy, management believes the Company has sufficient liquidity to fund its operations, working capital needs, and strategic initiatives for the 12 months following the issuance of the financial statements. Management will continue to monitor operating performance, cash flows, and capital requirements and may evaluate additional financing, strategic partnerships, or capital market opportunities if such transactions are deemed beneficial to the Company and its stockholders.
The Company expects to continue funding operations from cash on hand, cash generated from operations, investment income, and revenues from the licensing and sale of its products. Although management may consider additional equity, debt, or strategic financing alternatives in the future, there can be no assurance that such financing arrangements would be available on favorable terms or at all.
The following table presents overall liquidity and capital resources as of September 30, 2026 and June 30, 2026. Table amounts are in thousands:
| | | | | | | | | | | | | | |
| | September 30, | | June 30, |
| | 2026 | | 2026 |
| Current Ratio: | | | | |
| Current assets | | $7,700 | | $7,012 |
| Less: Current liabilities | | 2,833 | | 2,388 |
| Working capital | | $4,867 | | $4,624 |
| Current ratio | | 2.72 to 1 | | 2.94 to 1 |
| Debt to Total Capital Ratio: | | | | |
| Note payable, lease liabilities, and EIDL loan | | $1,257 | | $975 |
| | | | |
| Total equity | | 6,197 | | 5,928 |
| Total capital | | $7,454 | | $6,903 |
| Total debt to total capital | | 16.9% | | 14.1% |
Working Capital Position
Working capital increased approximately $243,000 to $4,867,000 as of September 30, 2026, and the current ratio changed to 2.72 to 1 when compared to June 30, 2026. The increase in working capital is mainly driven by net operating income.
Debt to total capital ratio was 16.9% and 14.1% as of September 30, 2026, and June 30, 2026, respectively. The increase is mainly due to lease liabilities additions.
Cash Flow Provided by Operating Activities
During the three months ended September 30, 2026, the Company provided by approximately $603,000 of cash in operating activities as compared to approximately $85,000 of cash provided by operating activities during the three months ended September 30, 2025.
For the three months ended September 30, 2026, its cash provided by operations is mainly due to net income of $269,000, an increase in accounts payable of $291,000, and an increase in deferred revenue of $116,000, offset by an increase in inventories of 102,000. The remaining offsetting items for cash used in operations is comprised of less significant items.
For the three months ended September 30, 2025, its cash provided by operations is mainly due to net loss of 240,000, a decrease in inventories of 396,000 and an increase in accrued expenses of $114,000, and a decrease in accounts receivable of $255,000, offset by a decrease in accounts payable of $207,000, and an increase in other current assets of $103,000 and a decrease in deferred revenue of $50,000. The remaining offsetting items for cash used in operations is comprised of less significant items.
Cash Flows Used in Investing Activities
There were no cash flows provided by or used in investing activities for the three months ended September 30, 2026. Cash flows used in investing activities for the three months ended September 30, 2025 was due to purchase of the fixed assets of $4,000.
Any necessary capital expenditures have generally been funded out of cash from operations, The Company is not aware of any factors that would cause historical capital expenditure levels to not be indicative of capital expenditures in the future. Accordingly, the Company does not believe that it will have to commit material resources to capital investment for the foreseeable future.
Cash Flows Used in Financing Activities
For the three months ended September 30, 2026, the cash used in financing activities was due to repayment of EIDL loan of $1,000.
For the three months ended September 30, 2025, the cash used in the financing activities of $11,000 was attributed to repayment of notes payable of $10,000, and repayment of EIDL loan of $1,000.
Off-balance Sheet Arrangements and Contractual Obligations
The Company was not a party to any off-balance sheet arrangements as of September 30, 2026, and June 30, 2026.
Item 3. Quantitative and Qualitative Disclosures About Market Risk
As a small reporting company, the Company is not required to provide the information required by this item.
Item 4. Controls and Procedures
(A) Evaluation of Disclosure Controls and Procedures
The Company's management, with the participation of the Company's Chief Executive Officer and Principal Financial and Accounting Officer, have established disclosure controls and procedures to ensure that material information relating to the Company, including its consolidated subsidiaries, is made known to the officers who certify the Company's financial reports and to other members of senior management and the Board of Directors.
Based on their evaluation of the effectiveness of the Company's disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of September 30, 2026, the Chief Executive Officer and Principal Financial and Accounting Officer of the Company have concluded that such disclosure controls and procedures are not effective to ensure that the information required to be disclosed by the Company in reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in SEC rules and forms, and that information required to be disclosed in the reports that the Company files or submits under the Exchange Act is accumulated and communicated to the Company's management, including its Chief Executive Officer and Principal Financial and Accounting Officer, to allow timely decisions regarding required disclosure. We identified a material weakness in internal control related to the proper design and implementation of controls over our estimates relating to the valuation of inventory specifically over the precision of management’s review during the year end June 30, 2023 and the remedies taken were not sufficient to change the management's conclusion on the internal control over financial reporting during the year end June 30, 2026.
(B) Internal Control over Financial Reporting
There have not been any changes in the Company's internal control over financial reporting (as such term is defined in Rule 13a-15(f) under the Exchange Act), during the first quarter ended September 30, 2026 that have materially affected, or are reasonably likely to materially affect, the Company's internal control over financial reporting. However, as noted above, we will continue to implement changes to our internal control over financial reporting to address the material weakness described above.
PART II. OTHER INFORMATION
Item 1. Legal Proceedings
This information set forth under Note 8, “Commitments and Contingencies” to the unaudited condensed consolidated financial statements included in Part I, Item 1 of this Quarterly Report on Form 10-Q is incorporated herein by reference.
Item 1A. Risk Factors
As a small reporting company, the Company is not required to provide the information required by this Item.
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds
None.
Item 3. Defaults Upon Senior Securities
None.
Item 4. Mine Safety Disclosures
Not applicable.
Item 5. Other Information
During the fiscal quarter ended September 30, 2026, no director or officer of the Company adopted or terminated any “Rule 10b5-1 trading arrangement” or any “non-Rule 10b5-1 trading arrangement” (as such terms are defined in Item 408 of Regulation S-K).
Item 6. Exhibits
31.1 Certification of Chief Executive Officer under Rule 13a-14(a).
31.2 Certification of Principal Financial and Accounting Officer under Rule 13a-14(a).
32.1 Certification of Chief Executive Officer under Section 1350 of Title 18 of the United States Code.
32.2 Certification of Principal Financial and Accounting Officer under Section 1350 of Title 18 of the United States Code
101.INS Inline XBRL Instance Document.
101.SCH Inline XBRL Taxonomy Extension Schema Document
101.CAL Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF Inline XBRL Taxonomy Extension Definition Linkbase Document
101.LAB Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE Inline XBRL Taxonomy Extension Presentation Linkbase Document
104 Cover Page Interactive Data File (embedded within the Inline XBRL document and contained in Exhibit 101 )
Signatures
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| | | | | | | | | | | | | | |
| | | | |
| | Escalon Medical Corp. | | |
| | (Registrant) | | |
| | | | |
| Date: November 16, 2026 | | By: | | /s/ Richard J. DePiano, Jr. |
| | | | Richard J. DePiano, Jr. |
| | | | Chief Executive Officer |
| | | | |
| Date: November 16, 2026 | | By: | | /s/ Mark Wallace |
| | | | Mark Wallace |
| | | | Chief Operating Officer and Principal Accounting & Financial Officer |